Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...

Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is ...

Eli Lilly and Rigel reach $960 million collaboration on RIPK1 inhibitors WuXi AppTec's market value exceeds 400 billion yuan, up more than 9% from opening high to closing high Shenqi Pharmaceuticals ...